Making Stem Cells Available for Therapy
New Product
The C2C_ASC product is based on mesenchymal stem cells (MSC) derived from healthy donor adipose tissue.
We aim to make stem cell therapies available for patients with unmet needs
Cell to Cure is a clinical-stage biopharmaceutical company developing cell-based therapies using allogeneic adipose tissue-derived mesenchymal stromal/stem cells for cellular therapies.
Clinical-Stage
Biotherapy
Cell to Cure ApS is a Danish clinical stage biopharmaceutical company focused on developing and delivering easy-to-use, off-the-shelf allogeneic adipose tissue-derived mesenchymal stromal/stem cells for patients with serious unmet medical needs.
Our cell therapy product has demonstrated a strong safety profile in more than 300 patients and is currently being evaluated in Phase I and II clinical trials, showing promising early results.
Cell to Cure develop new clinical stem cell therapies in “in house” projects, and in collaboration with partners worldwide.
Learn more about Cell to Cure
Our Cell Therapy
Mesenchymal cell therapy is regenerative medicine that involves the administration of living cells to a patient, aiming to treat or cure diseases. The goal is to repair, rebuild, or reestablish tissue homeostasis of damaged or compromised tissues and organs.
Mesenchymal Cell Therapy
Mesenchymal Cell therapy is regenerative medicine that involves the administration of living cells to a patient, aiming to treat or cure diseases.
Mode of action
Our stem cell product helps repair and regenerate tissue by signaling to other cells, interacting with the immune system, and supporting natural repair processes.
Our cell product
We develop ready-to-use, allogeneic adipose tissue-derived mesenchymal stromal/stem cells that help repair and regenerate tissue.
Cell Manufacturing
Our stem cell products are GMP-certified and ready-to-use for both clinical trials and research.
